Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus
- 8 April 2019
- journal article
- conference paper
- Published by Springer Nature in Gene Therapy
- Vol. 26 (6) , 250-263
Abstract
Recombinant Adeno-associated viruses (AAVs) are an attractive vector for gene therapy delivery which may be blocked by AAV neutralising antibodies (NAbs). As Type 1 Diabetes (T1DM) is an endocrine disease of immunological origin, it is likely that NAb profiles are altered in the disease. In this study NAb to AAV2, AAV5, AAV6, and AAV8 in 72 subjects with T1DM and 45 non-diabetic patients were measured over a 4-year follow-up period. AAV2 NAb titres were significantly lower in non-diabetic subjects (P = 0.036). The T1DM group had more AAV8 NAb activity at baseline (P = 0.019), whilst after 4 years follow-up the T1DM group displayed developed increased AAV 5 (P = 0.03), 6 (P = 0.03) and 8 (P = 0.002) activity relative to the control group, however, overall AAV5 and 8 NAb levels were very low in patients <40. AAV NAb titre activity and prevalence generally appears higher in T1DM, however, low levels of AAV 5 and 8, particular in younger adult age groups at which T1DM can be targeted, could make these attractive vectors to target the disease.Keywords
Funding Information
- Gallipoli Medical Research Foundation
- LVF Ophthalmology Research Centre
- -
- Juvenile Diabetes Research Foundation Australia (JDRFI 8-2008-362, JDRFI 8-2008-362)
This publication has 60 references indexed in Scilit:
- Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B1 and Type 1 DiabetesDiabetes, 2014
- A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotypeVirology Journal, 2013
- Gene Therapy for Retinitis Pigmentosa Caused by MFRP Mutations: Human Phenotype and Preliminary Proof of ConceptHuman Gene Therapy, 2012
- Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal ModelsMolecular Therapy, 2012
- Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and TreatmentsDiabetes Care, 2010
- Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscleNature Biotechnology, 2010
- A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Müller CellsPLOS ONE, 2009
- Subretinal delivery of adeno‐associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent miceThe Journal of Gene Medicine, 2009
- Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalitiesClinical and Experimental Immunology, 2007
- Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapyBlood, 2006